OOIR: Observatory of International Research

Papers

(The H4-Index of JHEP Reports is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper	311
Limitations of non-invasive tests for assessment of liver fibrosis	121
Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic	105
Non-alcoholic fatty liver disease: A patient guideline	104
NAFLD and liver transplantation: Disease burden, current management and future challenges	88
Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet – a randomised controlled trial	81
Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors	78
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma	78
Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment	77
New targets for NAFLD	72
Organoids to model liver disease	69
Lipid alterations in chronic liver disease and liver cancer	64
Where does TIPS fit in the management of patients with cirrhosis?	61
Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction	60
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma	55
Single-cell RNA sequencing of human liver reveals hepatic stellate cell heterogeneity	55
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy	50
Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B	50
NAFLD and MAFLD as emerging causes of HCC: A populational study	50
Novel vectors and approaches for gene therapy in liver diseases	50
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study	49
Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease	49
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area	49
The liver matrisome – looking beyond collagens	48
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg	45

Gut dysbiosis as a driver in alcohol-induced liver injury	44
Granulocyte colony-stimulating factor for alcoholic hepatitis: A systematic review and meta-analysis of randomised controlled trials	43
New frontiers in liver resection for hepatocellular carcinoma	41
Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy	36
Higher phenolic acid intake independently associates with lower prevalence of insulin resistance and non-alcoholic fatty liver disease	35
Combined alcoholic and non-alcoholic steatohepatitis	34
Assessing the impact of COVID-19 on liver cancer management (CERO-19)	34
Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD	34
Nuclear deformation mediates liver cell mechanosensing in cirrhosis	33
Extended hypothermic oxygenated machine perfusion enables ex situ preservation of porcine livers for up to 24 hours	33
Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases	33